Disorder of multiple glycosylation
MONDO:00177499 clinical trials for this condition and its sub-types, 0 tagged with Disorder of multiple glycosylation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disorder of multiple glycosylation
-
GNE myopathy 3 trials
-
Reunion island Larsen syndrome 1 trial
-
Immunodeficiency 23 1 trial
-
CCDC115-CDG 0 trials
-
TMEM199-CDG 0 trials
-
Defect in V-ATPase 0 trials
-
7 sub-types
- COG1-congenital disorder of glycosylation 0 trials
- COG4-congenital disorder of glycosylation 0 trials
- COG5-congenital disorder of glycosylation 0 trials
- COG6-congenital disorder of glycosylation 0 trials
- COG7-congenital disorder of glycosylation 0 trials
- COG8-congenital disorder of glycosylation 0 trials
- Congenital disorder of glycosylation, type IIq 0 trials
-
New drug UX016 targets rare muscle disease
Disease control Recruiting nowThis early-stage trial tests UX016, a drug designed to help people with GNE myopathy, a rare genetic muscle-weakening disease. Researchers will give the drug or a placebo to 24 adults to see if it is safe and improves muscle strength. The study is not yet recruiting.
Phase 1/2 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Hope for rare immune disease: new drug enters final testing
Disease control Recruiting nowThis study tests an experimental drug called AVTX-803 in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic condition that weakens the immune system and leads to frequent infections. The trial will compare the drug against a period without treatment to see…
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental sugar therapy tested for ultra-rare immune disorder
Disease control Recruiting nowThis phase 3 study is testing the long-term safety and effectiveness of AVTX-803, a form of L-fucose, in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic disorder that weakens the immune system. Only 2 participants who completed a previous study are enro…
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC